IBD

Spyre Therapeutics to Participate in Upcoming Investor Conference

Retrieved on: 
Tuesday, September 10, 2024
Engineering, IBD, Inflammation, Therapy, SYRE, Inflammatory bowel disease, Medicine

WALTHAM, Mass., Sept. 10, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in a fireside chat and investor meetings at the Stifel 2024 Virtual Immunology and Inflammation Summit.

Key Points: 
  • WALTHAM, Mass., Sept. 10, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in a fireside chat and investor meetings at the Stifel 2024 Virtual Immunology and Inflammation Summit.
  • Details of the fireside are as follows:
    A webcast replay will be available on the Spyre investor events website for 90 days following the event.

Centaurus Financial again named among top independent broker/dealers

Retrieved on: 
Tuesday, September 10, 2024
Financial plan, IBD, FP, CFP, Weather, Family, Financial adviser

ANAHEIM, Calif., Sept. 10, 2024 /PRNewswire/ -- Centaurus Financial, Inc. has been named one of the top U.S. independent broker/dealers by Financial Planning, based on revenue. Its "2024 IBD Elite" list, the news service writes, proves that small and medium-size firms will be able to weather whatever financial storms are ahead.

Key Points: 
  • 18 in Financial Planning's '2024 IBD Elite' list
    ANAHEIM, Calif., Sept. 10, 2024 /PRNewswire/ -- Centaurus Financial, Inc. has been named one of the top U.S. independent broker/dealers by Financial Planning, based on revenue.
  • Its " 2024 IBD Elite " list, the news service writes, proves that small and medium-size firms will be able to weather whatever financial storms are ahead.
  • Small and medium-size IBDs are "evolving to meet the demands of financial advisors and their clients, in some ways more quickly and effectively than the largest conglomerates," FP writes.
  • Centaurus continues to maintain its standing in the top 25 of independent broker/dealers in the U.S. Total revenue in 2023, the last year for which figures are available, was $202.5 million.

Viome Raises $25M To Launch Diagnostic Division and Bring On Former Amazon SVP and Samsung Chief Digital Officer, Kal Raman, as Chief Operating Officer

Retrieved on: 
Tuesday, September 10, 2024
News, Patient, Otorhinolaryngology, FDA, Automation, Digital, IBS, Cancer, Yoy, Health, Conditional sentence, Marketing, Samsung, Artificial intelligence, Biomarker, Ageing, IBD, Dentistry, Amazon, Khosla Ventures, SVP

BELLEVUE, Wash., Sept. 10, 2024 /PRNewswire/ -- Viome, a pioneer in microbiome health science and personalized health solutions, today announced a $25 million internal Series D with participation from Khosla Ventures, Bold Capital WRG Ventures, Marc Benioff, and more. This continued support from existing backers underscores their confidence in the company's innovative approach and growth trajectory, reflected in its projected YoY increase. The capital will be used to help launch Viome's diagnostic division and bolster its offerings as well as bring on Kal Raman as Chief Operating Officer to spearhead these initiatives. This news marks a significant milestone in supporting Viome's mission to revolutionize early disease detection and preventative health care, furthering our unwavering commitment to making illness optional and early detection accessible to all.

Key Points: 
  • The capital will be used to help launch Viome's diagnostic division and bolster its offerings as well as bring on Kal Raman as Chief Operating Officer to spearhead these initiatives.
  • Kal Raman, known for his visionary leadership at Amazon, Groupon, and Samsung, brings a wealth of experience to Viome.
  • "What attracted me to Viome was its mission to have a meaningful impact on the health of individuals," said Kal Raman.
  • Every step Viome takes, including hiring Kal Raman, is rooted in our mission to make illness optional.

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Retrieved on: 
Monday, September 9, 2024
Other Health, Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Health, Human, Trial of the century, Biology, IBD, Cytokine release syndrome, Safety, Lymph, CD20, Ulcerative colitis, Inflammation, Antibody, Bone marrow, Patient, Protein engineering, Engineering, Inflammatory Bowel Diseases, Immune system, Autoimmunity, CD28, Biomarker, TL1A, ENPP3, IL23, Telephone, PSA, FC, Half-life, News, CD19, RECIST, Cancer, Pembrolizumab, Vaccine

Xencor’s XmAb 2+1 multivalent format used in XmAb819 enables greater selectivity of ENPP3-expressing tumor cells compared to normal cells, which express lower levels of ENPP3.

Key Points: 
  • Xencor’s XmAb 2+1 multivalent format used in XmAb819 enables greater selectivity of ENPP3-expressing tumor cells compared to normal cells, which express lower levels of ENPP3.
  • Clinical update: The majority of patients enrolled into the ongoing Phase 1 dose-escalation study are men with metastatic castration-resistant prostate cancer (mCRPC).
  • Xencor previously completed a Phase 1 clinical study of plamotamab in hematologic cancers, completing enrollment in late 2023.
  • The live webcast may be accessed through “Events & Presentations” in the Investors section of the Company’s website, located at investors.xencor.com .

NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines

Retrieved on: 
Thursday, September 5, 2024
Health, Biometrics, Health Technology, Clinical Trials, Pharmaceutical, Biotechnology, AbbVie, NIMML, Psoriasis, Acquisition, IBD, Lupus, Organization, Ulcerative colitis, Asthma, Pathology, Rheumatoid arthritis, Partnership, Therapy, Research, ABBV, Drug development, Disease, Patient, Autoimmune disease, Ecosystem, Pharmaceutical industry

NImmune Biopharma ("NImmune”), a late-clinical-stage precision immunology biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics, today announced a research collaboration with BioTherapeutics, Inc. (“BioTherapeutics”), a clinical-stage biotech company that combines advanced computational modeling with translational and clinical experimentation to accelerate the development of novel products.

Key Points: 
  • NImmune Biopharma ("NImmune”), a late-clinical-stage precision immunology biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics, today announced a research collaboration with BioTherapeutics, Inc. (“BioTherapeutics”), a clinical-stage biotech company that combines advanced computational modeling with translational and clinical experimentation to accelerate the development of novel products.
  • The collaboration strengthens NImmune’s precision immunology capabilities by providing access to BioTherapeutics’ preclinical services and regulatory capabilities for product testing, mechanism of action validation studies, and development of animal and computational models of inflammatory and autoimmune disease.
  • NImmune will also gain access to BioTherapeutics’ proprietary animal models of disease, including its unique pig models of IBD, PK/PD analysis capabilities and expert regulatory infrastructure.
  • “We look forward to the ongoing collaboration between BioTherapeutics and NImmune, as well as the NIMML Institute, to significantly accelerate the clinical development of our high-conviction drug candidates.”

Ovation.io and PD Theranostics (PDTx) Complete Merger Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific Biospecimens

Retrieved on: 
Thursday, September 5, 2024
Liver disease, IBD, Genetics, Patient derived xenograft, Vaccine, MGH, The Ovation, Cell, Gene expression, Tissue, Blood, Cancer, Pathology, Protein, Chronic kidney disease, Immune system, Hospital, Research, Genomics, Biomarker, Cell biology, Drug development, Disease, DNA, Patient, RNA, Inflammatory bowel disease, VIC, CKD, Alzheimer's disease, Clinical trial, Prostate cancer, Massachusetts General Hospital, Medical imaging

The new entity creates an industry-leading multiomics data company managed by a team with deep expertise in genomics data, sequencing, bioinformatics, cell biology, and imaging, AI/ML and data commercialization.

Key Points: 
  • The new entity creates an industry-leading multiomics data company managed by a team with deep expertise in genomics data, sequencing, bioinformatics, cell biology, and imaging, AI/ML and data commercialization.
  • "We believe the two companies are deeply complementary and will provide our customers with best-in-class, diverse multiomics data," said Curt Medeiros, CEO of Ovation.
  • "The in-house biobank will allow the team to accelerate data generation and more fully leverage the PDTx platform's high dimensional, multiomic modalities that characterize cellular status.
  • Connecting genetic data with cellular, structural and chemical details of tissue affected by IBD or prostate cancer can lead to important translational medical progress.

Lucius Partners Portfolio Company, PD Theranostics, Completes its Merger with Ovation.io Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific Biospecimens

Retrieved on: 
Thursday, September 5, 2024
Liver disease, IBD, Genetics, Patient derived xenograft, Vaccine, MGH, The Ovation, Cell, Gene expression, Tissue, Blood, Cancer, Pathology, Protein, Chronic kidney disease, Immune system, Hospital, Research, Genomics, Biomarker, Cell biology, Drug development, DNA, Patient, RNA, Inflammatory bowel disease, VIC, CKD, Alzheimer's disease, Clinical trial, Prostate cancer, Massachusetts General Hospital, Medical imaging

The new entity creates an industry-leading multiomics data company managed by a team with deep expertise in genomics data, sequencing, bioinformatics, cell biology and imaging, AI/ML and data commercialization.

Key Points: 
  • The new entity creates an industry-leading multiomics data company managed by a team with deep expertise in genomics data, sequencing, bioinformatics, cell biology and imaging, AI/ML and data commercialization.
  • "We believe the two companies are deeply complementary and will provide our customers with best-in-class, diverse multiomics data," said Curt Medeiros, CEO of Ovation.
  • This will help drive our client's R&D efforts, from target and biomarker discovery, through optimized clinical trial enrollment."
  • "The unique capabilities it creates will speed the development of cost-saving, efficacious, patient-driven solutions for the healthcare industry and continue to enhance shareholder value.

Dr. Brittany Mitchell Joins Washington Gastroenterology in Silverdale

Retrieved on: 
Friday, August 23, 2024
IBD, Inflammatory bowel disease, Health, University of California, Irvine, Irritable bowel syndrome, Suite, University, University of Michigan, Gastroenterology, Colonoscopy, Cleveland Clinic, Liver disease, IBS, University of Washington, Nursing

Silverdale, WA, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Washington Gastroenterology is proud to welcome Dr. Brittany Mitchell, a board-certified gastroenterologist who treats all general GI conditions while specializing in liver disease, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and colonoscopy.

Key Points: 
  • Silverdale, WA, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Washington Gastroenterology is proud to welcome Dr. Brittany Mitchell, a board-certified gastroenterologist who treats all general GI conditions while specializing in liver disease, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and colonoscopy.
  • Dr. Mitchell got her undergraduate degree from University of Michigan, then her medical degree from University of California at Irvine.
  • Dr. Mitchell completed her residency at Cleveland Clinic and her fellowship at University of Washington.
  • “Our digestive system plays such an enormous role in our overall health, which was a big reason why I chose gastroenterology,” says Dr. Mitchell.

The STAR Consortium Announces a Major Milestone in Crohn's Disease Intestinal Strictures Imaging

Retrieved on: 
Wednesday, August 21, 2024
IBD, Mayo Clinic, Health, STAR, Biotechnology, Stenosis, MRI, CT scan, Fibrosis, Crohn's disease, Knowledge, Gastroenterology, Biomarker, Surgeon, Research, Inflammatory Bowel Diseases, Cleveland Clinic, Helmsley, Patient, Clinical trial, Failure, Disease, Inflammation, Pharmaceutical industry

NEW YORK, Aug. 21, 2024 /PRNewswire/ -- In a recent innovation for Crohn's disease treatment, researchers from the Stenosis Therapy and Anti-Fibrotic Research (STAR) consortium have developed reliable methods to measure intestinal strictures using both MRI and CT imaging. This advancement, published in Radiology, marks a significant step toward effective medical therapies for Crohn's disease-related intestinal strictures.

Key Points: 
  • Crohn's disease can cause narrowing of the bowel, known as intestinal strictures, due to the buildup of scar tissue (called fibrosis), muscular thickening, and inflammation.
  • The STAR consortium is dedicated to transforming the treatment of Crohn's disease strictures with their research, extending beyond developing imaging-based methods.
  • The STAR consortium consolidates and shares knowledge of Crohn's disease strictures with leading academic research institutions across the globe, and pharmaceutical and biotechnology partner organizations.
  • The STAR consortium is working to share its experience and knowledge with regulatory agencies, pharmaceutical organizations, and medical societies to improve patient care and clinical outcomes for patients with Crohn's disease and intestinal strictures.

questhealth.com Introduces 13 New Blood Tests to Identify Micronutrient Deficiencies

Retrieved on: 
Thursday, August 15, 2024
Proton, Quest Diagnostics, Inflammatory bowel disease, Health, DGX, Milk, Nutrition, Food, Coeliac disease, Doctor of Pharmacy, Nutrient, Risk, Calcium, Mineral, Thyroid, Calcium channel, Senior, IBD, Vitamin, COVID-19, Magnesium, Micronutrient, Allergy, Iron, Research, Depression, Dietary supplement

SECAUCUS, N.J., Aug. 15, 2024 /PRNewswire/ -- Micronutrients are essential vitamins and minerals that are vital for well-being and disease prevention, but deficiencies can commonly be caused by food allergies and dietary restrictions, certain prescription medications, or chronic health conditions. At least one in three Americans are at risk of nutrient deficiencies1. Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the availability of 13 blood tests designed to evaluate micronutrient deficiencies, helping people identify if they are lacking certain vitamins and minerals needed by the body to maintain optimal health. These panels are now available for consumer purchase exclusively at questhealth.com.

Key Points: 
  • Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the availability of 13 blood tests designed to evaluate micronutrient deficiencies, helping people identify if they are lacking certain vitamins and minerals needed by the body to maintain optimal health.
  • Research has linked both prescription medication and chronic health conditions with potential treatment-induced, or disease-state induced, micronutrient deficiencies, respectively.
  • "Whether micronutrient deficiencies stem from dietary restrictions, medications, or chronic conditions, our tests provide consumers with valuable tools to take better control over their health."
  • Unlike traditional direct-to-consumer tests, each of the Quest lab tests available on questhealth.com involve physician oversight.